Ulrich Krause

Dr. Ulrich Krause


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2012 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
HSHeike E. Schneider
Heike E. Schneider
MSMichael Steinmetz
Michael Steinmetz
UKUlrich Krause
Ulrich Krause
TKThomas Kriebel
Thomas Kriebel
WRWolfgang Ruschewski
Wolfgang Ruschewski
TPThomas Paul
Thomas Paul
Background Left cardiac sympathetic denervation (LCSD) may be a therapeutic adjunct for young patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) and long QT syndrome (LQTS) who are not fully protected by beta-blockade. Objective The objective of this analysis was to report our institutional experience with LSCD in young patients for the management of life-threatening ventricular arrhythmias in CPVT and LQTS. Methods Ten young patients with CPVT and LQTS underwent transaxillary LSCD at our institution. Mean age at surgery was 14.0 (range 3.9–42) years, mean body weight was 45.7 (range 15.5–90) kg. Five patients had the clinical diagnosis of CPVT, three were genotype positive for a mutation in the ryanodine-receptor-2-gene. Four of five LQTS patients were genotype positive. Indications for LCSD were recurrent syncope, symptomatic episodes of ventricular tachycardias and/or internal cardioverter–defibrillator (ICD) discharges, and aborted cardiac arrest despite high doses of beta-blockers. Results LCSD was performed via the transaxillary approach. No significant complications were observed. Two patients already had an ICD, 6 patients received an ICD at the same operation or shortly thereafter. Median length of follow-up after LCSD was 2.3 (range 0.6–3.9) years. After LCSD a marked reduction in arrhythmia burden and cardiac events was observed in all patients while medication was continued. None of the patients had any further ICD discharge for sustained VT. Conclusions After LCSD, arrhythmia burden could significantly be reduced in all our young patients with CPVT and LQTS.

14 September 2011 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
UKUlrich Krause
Ulrich Krause
VGV. Gravenhorst
V. Gravenhorst
TKThomas Kriebel
Thomas Kriebel
WRW. Ruschewski
W. Ruschewski
TPT. Paul
T. Paul

19 December 2023 in Circulation
Verified
Journal Article
Open access
ABAuke T. Bergeman
Auke T. Bergeman
KLKrystien V.V. Lieve
Krystien V.V. Lieve
DKDania Kallas
Dania Kallas
JBJ. Martijn Bos
J. Martijn Bos
FNFerran Rosés i Noguer
Ferran Rosés i Noguer
CWChristian van der Werf
Christian van der Werf
BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14–29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7–3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4–7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0–6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38–0.83]; P =0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31–0.77]; P =0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14–0.45]; P <0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.

26 February 2014 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
UKUlrich Krause
Ulrich Krause
KBKristin Becker
Kristin Becker
GHGünter Hahn
Günter Hahn
JDJörg Dittmar
Jörg Dittmar
WRWolfgang Ruschewski
Wolfgang Ruschewski
TPThomas Paul
Thomas Paul

29 May 2014 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
DBDavid Backhoff
David Backhoff
MMMatthias Müller
Matthias Müller
WRWolfgang Ruschewski
Wolfgang Ruschewski
TPThomas Paul
Thomas Paul
UKUlrich Krause
Ulrich Krause

28 October 2015 in EP Europace
Verified
Journal Article
Closed access
PDF file
UKUlrich Krause
Ulrich Krause
DBDavid Backhoff
David Backhoff
SKSophia Klehs
Sophia Klehs
HSHeike E. Schneider
Heike E. Schneider
TPThomas Paul
Thomas Paul
Aims Catheter ablation of atrial re-entrant tachycardia in patients after atrial switch procedure for transposition of the great arteries or with a Fontan circulation is technically challenging if the critical part of the re-entry circuit is located within the pulmonary venous atrium (PVA). We report our experience in transbaffle access (TBA) to the PVA for ablation of atrial re-entrant tachycardia focusing on technical details. Methods and results In eight patients, six after Mustard procedure and two with a Fontan circulation, endocardial mapping of atrial re-entrant tachycardia revealed the critical part of the re-entry circuit within the PVA. A total of 10 ablation procedures were performed. Detailed angiographic assessment of the anatomy of the systemic and pulmonary venous atria was performed prior to baffle puncture. Transbaffle access was successfully established with a standard transseptal needle in 9 of 10 procedures. No major complications occurred. At the end of the procedure and the removal of the transseptal sheath, there was no residual shunt in any patient. Conclusion Transbaffle access to the PVA for ablation of atrial re-entrant tachycardia is feasible, less invasive than alternative approaches and can be safely applied in patients after Mustard procedure or with a Fontan circulation. However, the rigidity of prosthetic material may preclude baffle puncture at least in a subset of those patients.